CRCT - Centre de Recherches en Cancérologie de Toulouse

What CRCT - Centre de Recherches en Cancérologie de Toulouse does

CRCT (Centre de Recherches en Cancérologie de Toulouse / Toulouse Cancer Research Center) is a public, non-profit cancer research institution located at the Toulouse Oncopole campus in France, operating as a joint research unit (UMR 1037) under the joint supervision of INSERM, CNRS (UMR 5071), and Université Toulouse III Paul Sabatier. Founded as a UMR in 2011 and installed at the Oncopole campus since September 2014 within a 13,000+ m² facility financed at over €41 million by regional, national, and European public funders, CRCT is directed by Dr. Pierre Cordelier (appointed September 1, 2023). The center conducts basic and translational oncology research across 18 research teams organized around four scientific axes: oncogenic signaling and DNA damage, RNA & cancer, tumor microenvironment and metabolism, and onco-immunology, with a community of approximately 389 researchers, engineers, technicians, doctoral students, and hospital practitioners.

The center's core technical infrastructure comprises nine technology platforms — bioinformatics, cytometry and cell sorting, genomics and transcriptomics, cellular imaging (including LSM780/LSM980 Airyscan2 confocal microscopes, Opera Phenix high-content screening, Incucyte live-cell imaging, and Phenocycler-Fusion spatial proteomics), irradiator, molecular interactions BIA, vectorology, and experimental histology — supported by the Labex TOUCAN excellence programme (ANR Investissements d'Avenir), the IRIT@CRCT Digital Cancer Laboratory "Michel Laudet," and the NeoVirTech theranostics platform. CRCT also operates the #CRCT Scholar training programme in connection with the CARe Graduate School.

CRCT does not sell commercial products; its operating model is grant-funded and partnership-driven. Funding comes from institutional allocations by INSERM, CNRS, and the host university; competitive grants from ANR, INCa, and the European Research Council (including a 2025 ERC Starting Grant); multi-year labellizations from charitable foundations (Ligue Contre le Cancer, Fondation ARC, Fondation Toulouse Cancer Santé); and collaborative research agreements with pharmaceutical partners including Roche, Pierre Fabre, Sanofi, GSK, AstraZeneca, and Novartis. The center's primary "customers" in a service-delivery sense are academic and clinical cancer researchers, hospital partners (IUCT-O, CHU de Toulouse), and industry collaborators, with research outputs distributed through peer-reviewed publications, technology platform services, doctoral training, and translational projects.

Name

CRCT - Centre de Recherches en Cancérologie de Toulouse

Legal name

Centre de Recherches en Cancérologie de Toulouse

Website

https://crct-inserm.fr

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

101–250 employees

Short description

CRCT is a public cancer research center at the Toulouse Oncopole, operating as UMR 1037 under INSERM, CNRS, and Université Toulouse III Paul Sabatier. It runs 18 research teams across four oncology axes and 9 technology platforms, serving clinical, academic, and pharmaceutical collaborators.

Ownership category

akta.pro rank

Product category

Cancer Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)

akta.pro secondary industries

Clinical Research & Trial Central Laboratories (HLAFAMAL), Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD)

Keywords

• Cancer research center
• Translational oncology
• Molecular oncology research
• Tumor biology research
• Biomedical research platforms

Headquarters

HQ city

Toulouse

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations

Revenue model

1. Public Research Funding: CRCT operates as a joint research unit (UMR 1037) primarily funded through institutional allocations from INSERM, CNRS, and Université Toulouse III Paul Sabatier. Additional funding comes from government research agencies including ANR (Agence Nationale de la Recherche) through programmes like Investissements d'Avenir (PIA).
2. Clinical and Charity Funding: Substantial funding from clinical partners (IUCT-O, CHU de Toulouse) and charitable cancer research foundations including Ligue Contre le Cancer, Fondation ARC, Fondation Toulouse Cancer Santé, and other patient associations.
3. Industry Partnerships: Collaborative research agreements with pharmaceutical companies (Roche, Pierre Fabre, Sanofi, GSK, AstraZeneca, Novartis, etc.) and biotechnology firms for translational research and drug development.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

CRCT (Toulouse Cancer Research Center) is a joint research unit (UMR 1037 INSERM, UMR 5071 CNRS, Université Toulouse III Paul Sabatier) conducting basic and translational cancer research. It operates 18 research teams organized around 4 scientific axes (oncogenic signaling/DNA damage, RNA & cancer, tumor microenvironment/metabolism, and onco-immunology) and provides 9 shared technology platforms covering bioinformatics, cytometry, genomics, cellular imaging, irradiation, molecular interactions, vectorology, and histology. The center also runs integrated research programmes including LabEx TOUCAN (ANR-funded hematological cancer resistance programme), IRIT@CRCT digital cancer laboratory, and NeoVirTech theranostics platform.

Product overview

CRCT is a cancer research center at Toulouse Oncopole (UMR 1037 Inserm, UMR 5071 CNRS, Université Toulouse III Paul Sabatier) with 18 research teams organized into 4 scientific axes: Oncogenic pathways, RNA & Cancer, Tumour microenvironment and metabolism, and Onco-immunology. The center provides technology platforms for bioinformatics, cytometry, genomics, cellular imaging, and other research services. Associated programs include LabEx TOUCAN (ANR-funded excellence laboratory), IRIT@CRCT digital laboratory, and NeoVirTech theranostics platform, all supporting integrated research between basic science and clinical applications.

Differentiator

Problem solved

Functional benefit

Brands

• LABEX TOUCAN: Laboratoire d'Excellence Toulouse Cancer - a research programme financed by the Agence Nationale de la Recherche (ANR) under the Programme des Investissements d'Avenir (PIA), aiming to understand mechanisms of resistance and relapse in hematological cancers.

Products and services

• CRCT Research Center
• LabEx TOUCAN

Named customers3 records

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Twelve partnerships are on record, tiered core and minor.

• INSERMcoreOthersINSERM (Institut National de la Santé et de la Recherche Médicale) is the primary institutional partner and supervisory body. CRCT is UMR 1037, jointly managed by INSERM, CNRS, and Université Toulouse III Paul Sabatier. INSERM owns the building at the Oncopole where CRCT is located.
• CNRScoreOthersCNRS (Centre National de la Recherche Scientifique) is a co-supervisory institution of CRCT (UMR 5071). Provides institutional support and funding alongside INSERM.
• Université Toulouse III Paul SabatiercoreOthersUniversity partner providing academic supervision and access to doctoral programs including CARe Graduate School. CRCT is co-managed as UMR.
• IUCT-O (Institut Universitaire du Cancer Toulouse-Oncopole)coreStrategic or Co-development PartnerMajor clinical partner combining Institut Claudius Regaud and CHU de Toulouse oncology teams. Provides clinical research integration, translational research programmes, and joint funding for cancer research projects.
• CHU de ToulousecoreStrategic or Co-development PartnerUniversity hospital with 3,900 physicians and 11,600 staff serving 280,000 patients annually. Clinical partner providing patient access and translational research opportunities.
• RocheminorOthersPharmaceutical partner listed among private industrial collaborators supporting CRCT research programmes.
• Pierre FabreminorOthersPharmaceutical partner listed among private industrial collaborators supporting CRCT research programmes.
• SanofiminorOthersPharmaceutical partner listed among private industrial collaborators supporting CRCT research programmes.
• GSKminorOthersPharmaceutical partner listed among private industrial collaborators supporting CRCT research programmes.
• AstraZenecaminorOthersPharmaceutical partner listed among private industrial collaborators supporting CRCT research programmes.
• NovartisminorOthersPharmaceutical partner listed among private industrial collaborators supporting CRCT research programmes.
• Labex TOUCAN PartnerscoreStrategic or Co-development PartnerLabex TOUCAN brings together six Toulouse research teams from CRCT and Institute of Pharmacology and Structural Biology (IPBS) to study resistance and relapse mechanisms in hematological cancers. Funded by ANR under Investissements d'Avenir.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• The Institute of Cancer Research (ICR): UK-based cancer research institute affiliated with the University of London and The Royal Marsden. Comparable to CRCT as a translational cancer research institution with strong pharma partnerships and academic affiliation.
• German Cancer Research Center (DKFZ): Germany's largest biomedical research institute focused on cancer. Comparable as a European national-scale oncology research center, though operating at materially larger scale and with broader resources than CRCT.
• INSERM (Institut National de la Santé et de la Recherche Médicale): French national biomedical research agency and CRCT's primary supervisory institution. Comparable as the parent governance structure under which CRCT operates, overseeing the broader French biomedical research ecosystem that CRCT is embedded within.
• Netherlands Cancer Institute (NKI): Dutch comprehensive cancer center combining research and clinical care. Comparable to CRCT as a European integrated translational oncology institution, though at larger scale with international recognition.

Direct peers

• Institut Gustave Roussy: France's leading comprehensive cancer center combining research, care, and teaching. Comparable to CRCT as a French oncology-focused research institution with integrated clinical-academic mission, though operating at substantially larger scale.
• Centre Léon Bérard: Lyon-based French comprehensive cancer center (CLB) combining research, clinical care, and translational oncology. Closest geographic peer to CRCT in the French oncology ecosystem with similar public hospital-CRLCC model.
• Institut Paoli-Calmettes: Marseille-based French comprehensive cancer center (CLCC) combining research and clinical oncology. Comparable to CRCT as a French regional oncology center with clinical-translational integration.
• Institut Curie: French cancer research and treatment center with hospital and research divisions focused on oncology. Directly comparable to CRCT as a French basic-translational cancer research institution with strong industry partnerships and clinical integration.
• Cancer Research Centre of Lyon (CRCL) - INSERM U1052 / CNRS UMR 5286: Lyon-based INSERM/CNRS cancer research center with comparable UMR structure and translational oncology programs. Directly comparable to CRCT as a French regional oncology research center with similar institutional setup.
• Institut de Recherche en Cancérologie de Montpellier (IRCM) / INSERM U1194: INSERM-affiliated cancer research center in Montpellier with similar UMR structure and translational research focus. Comparable to CRCT as a French regional cancer research unit under INSERM/CNRS governance.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/crctoncopole
• YouTubeyoutube.com/@centrerecherchescancerolog2300
• Facebookfacebook.com/crctoncopole
• LinkedInlinkedin.com/company/centre-de-recherches-en-cancerologie-de-toulouse

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CRCT - Centre de Recherches en Cancérologie de Toulouse